top of page

Latest News

Jul 14, 2026

Dr. Subrata Chakrabarti Highlights RNA Therapeutics for Diabetic Retinopathy at ADA 2026; Presentation Now Available on VuMedi

Dr. Subrata Chakrabarti Highlights RNA Therapeutics for Diabetic Retinopathy at ADA 2026; Presentation Now Available on VuMedi

Jan 26, 2026

New peer-reviewed study on lncRNA-targeting eyedrop approach for potential diabetic retinopathy therapy

New peer-reviewed study on lncRNA-targeting eyedrop approach for potential diabetic retinopathy therapy

Jan 23, 2026

i-RNA Corporation Kicks Off 2026 with Strategic Industry Engagements at OBIO® Investment Summit and ATTD 2026

i-RNA Corporation Kicks Off 2026 with Strategic Industry Engagements at OBIO® Investment Summit and ATTD 2026

May 26, 2025

i-RNA Corporation Receives Dual Awards at EFFERVESCENCE 2025

i-RNA Corporation Receives Dual Awards at EFFERVESCENCE 2025

Feb 21, 2025

i-RNA Corporation Partners with JLABS @ Toronto to Drive Innovation in Diabetic Retinopathy Therapy

i-RNA Corporation Partners with JLABS @ Toronto to Drive Innovation in Diabetic Retinopathy Therapy

Nov 7, 2024

i-RNA Corporation Launches with Pioneering RNA Therapies and Secures Key Intellectual Property Transfer

i-RNA Corporation Launches with Pioneering RNA Therapies and Secures Key Intellectual Property Transfer

Oct 25, 2024

i-RNA Corporation joins Johnson & Johnson Innovation - JLABS as a new resident company in Toronto!

i-RNA Corporation joins Johnson & Johnson Innovation - JLABS as a new resident company in Toronto!

Oct 23, 2024

Dr. Chakrabarti presents data on its RNA-based treatments of Diabetic Retinopathy at ISER in Argentina

Dr. Chakrabarti presents data on its RNA-based treatments of Diabetic Retinopathy at ISER in Argentina

bottom of page